Let’s reduce the risks together
Consider joining a clinical study If you have high blood pressure, diabetes and cardiovascular disease, our clinical study could be a good fit for you. While lifestyle changes and current medicines offer some protection, many people with these conditions still experience disease progression that increases their risk of further cardiovascular complications and kidney damage. That’s why we’re running a global clinical study called EASi-PROTKT™ that aims to find out whether combining an investigational medicine with an approved medicine called empagliflozin could help people reduce their risk of developing serious heart health events, including heart failure, in the future.
Please turn over to learn more.
What will taking part in this study involve?
If you’d like to take part, we’d first carry out some screening assessments to make sure that you and the study are a good fit. If you’re eligible and choose to join, you’ll be randomly assigned to one of two groups.
GROUP 1:
You’ll be given the investigational medicine and empagliflozin daily
GROUP 2:
You’ll be given a placebo (a tablet that looks like the investigational medicine but contains no active medicine) and empagliflozin daily’
You’ll be asked to take your assigned study medicines as two oral tablets daily for between 2.5 and up to 4.25 years. Your health and well-being will be closely monitored throughout the study with scheduled clinic visits and telephone calls. Health assessments will include: physical examinations, electrocardiograms (ECGs), and blood and urine samples. This health monitoring, along with the study medicines, will be provided at no cost to you, regardless of your insurance status. You may receive reimbursement for
accommodation and travel costs, in line with local regulations.
Participation is entirely voluntary and if you join the study, you may leave at any time with no impact on your regular healthcare.
Who can join this study?
We’re looking for approximately 11,800 adults from around the world, who, in addition to other criteria:
- Have been diagnosed with high blood pressure, type 2 diabetes, and cardiovascular disease (and are taking medicine for all three conditions)
What happens next?
If you’d like to learn more about the EASi-PROTKT™ study, please contact the study team using the details below. They’ll be happy to answer any questions you may have.
Study team contact information: 786-772-0510
